Search results for

There are various ways to pursue infringers and seek restitution. Agustín Velázquez, Gabriel Pardo, Alberto Huerta Bleck and Alvaro Huerta of Mijares Angoitia Cortes y Fuentes SC outline what is available to rights owners

José Graca-Aranha of WIPO discusses Mexico and the rest of Latin America's developing attitude towards joining the Madrid Protocol

The dispute surrounding geographical indications and their co-existence with trade marks created a deadlock in international trade negotiations in 2003. But discussions are now in full swing with two recent WTO decisions, an ECJ opinion and the upcoming WTO summit in Hong Kong. Stéphanie Bodoni reports

Technology transfer and licensing deals are governed by a series of national laws that foreign companies need to understand before doing business in Mexico. Jose Antonio Romero and Héctor Chagoya of Becerril Coca & Becerril outline the country's licensing regime

Emma Barraclough, San Diego

Spurred on by success in several cases, campaigners in developing countries want to reform the patent system to recognize the place of traditional knowledge. If change comes, it will have a big impact on all patent applicants in the life sciences industry. James Nurton and Emma Barraclough report

In E-Toyo Global Stationery v Toyo Ink [2005], the first respondent was the registered proprietor of the trade mark Toyo in Class 16 and had been the registered proprietor since 1979. In 2002, the first respondent entered into a registered user agreement with the second respondent to use the Toyo mark. In 2004, a third party (not a party to this action) became a registered user and gained a licence to use the Toyo mark by way of a novation cum registered user agreement with the first respondent. The applicant alleged that as a result of the 2002 registered user agreement, an act of so-called "trafficking" had been committed.

The Singapore Patents Act was amended on July 1 2004. The amendments have brought about various changes to the search and examination options available to applicants using the PCT route. The options available for applications with filing dates both before and after July 1 2004 are outlined below.

By their nature, life science companies are among the more IP-dependent businesses in the corporate world. Any transactions, therefore, will require a more thorough due diligence than is the norm. Paul M Booth and Leslie Mooi outline 10 things you should know about such a company before deciding to invest in, or acquire, it

According to Regulation 1768/92/EEC supplementary protection certificates (SPCs) can be granted for novel medicines. They are intended to compensate for the reduced effective lifetime of patents covering such medicines.